All COVID-19 vaccines now have emergency use authorization for a booster dose.
All COVID-19 vaccines now have emergency use authorization for a booster dose.
One-third of employees have witnessed cannabis use during work hours.
Pre-pandemic, 951 claims received telemedicine, jumping to 21,000 during the pandemic.
Visit Healthe at WCI booth #913! Plus, a recap of a SAWCA roundtable, featuring Sandy Shtab.
A new migraine medication, various generics, and more.
Long-term health impacts of COVID-19 can complicate claims
A WCRI study found that in some states 17% of workers receive topical analgesics.
Take our survey and share your thoughts on where the industry is headed.
Take part in our virtual speaking sessions at PRIMA and Comp Laude!
The Pfizer vaccine receives full FDA approval, while a new EUA authorizes booster shots for certain populations.
Healthe’s Director of Enterprise Analytics discusses in WorkCompWire how natural language processing can assist with claim review, population management, and more.
Less than 1% of gabapentin prescriptions were prescribed for an FDA-approved diagnosis.
All federal employees are impacted, as are companies with 100 or more employees.
Join our educational session on infectious disease safety in the workplace, and don’t miss a chance to take part in our industry survey!
The FDA approved first-time generics for Xeljanz, two COPD medications, and more.
Healthe’s Director of Product Management explains how centralized data helps claims professionals.
A new WCRI report explores the impact recent opioid legislation has had on injured worker care.
Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.
Not enough time for white papers or industry reports? Check out our Clinical Minute videos!
A joint statement announces that at this time, vaccinated adults are protected from the Delta variant.
Extensive isolation and unique stressors may impact the mental health of remote workers.
Changes center around improving the assessment of mental and behavioral impairment.
Connecticut legalizes recreational use, and NCCI expects even more states to follow suit.
Join our VP of Clinical Services on July 29th for a discussion on care and program considerations for underrepresented populations.
Wegovy (semaglutide) and sotrovimab will soon be available.
How to leverage the patient’s influence over care outcomes.
A new flash report from the WCRI highlights trends in drug utilization.
Corrections officers in Nebraska benefit from a new law; will healthcare workers in Connecticut join them?
Check out Healthe’s latest featured article with WorkCompWire
Join our VP of Clinical Services on July 15th for a discussion on underrepresented populations in workers' comp.
A new 8 mg naloxone nasal spray will soon be available, which is the largest naloxone dose approved by the FDA to date.
The latest issue of Healthesystems’ biannual clinical journal covers trending and influential topics in workers’ comp.
Our VP of Clinical Services comments on opioid alternatives, and our AVP of Advocacy & Compliance discusses social media in the workplace.
Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.
While many states are making decisions regarding gig workers, federal action could soon change things.
After reviewing six rare cases of blood clots after 7 million doses, current data indicates the vaccine is safe.
Applications, benefits and tips for success.
More states consider allowing injured workers to choose their treating physician.
In two months, three states legalized recreational marijuana, and more could soon follow.
Join Healthe’s Heather Stempien and Sandy Shtab for a panel presentation with IAIABC on April 28th!
A new 500mg injection will soon be available.
Over 600 stakeholders shared their thoughts on top industry challenges.
Among 1,600 emergency department workers, 46% had burnout symptoms.
Both State Supreme Courts ruled in favor of reimbursement.
The single-dose Janssen vaccine was analyzed in a trial of 39,000 patients.
A novel bupivacaine formulation works as a 72-hour local anesthetic following shoulder surgery.
Healthe leaders share their thoughts with Risk & Insurance®
New data from a safety trial creates concern surrounding the rheumatoid arthritis drug.
State-led efforts to combat the drug price issue continue to emerge across the nation.
Healthe’s AVP of Advocacy & Compliance will provide guidance on workers’ comp regulations.
Join us for a panel discussion on March 10th as part of the NWCDC Digital Session Series.
False negatives may be reported due to genetic variations of the virus.
Kristine Kennedy, SVP of Product Strategy and Innovation, talks to Risk & Insurance®
A new report from IQVIA found that national MME dropped 17% from 2019 to 2020.
The Department of Labor issued a new rule while special interest groups push for regulatory change.
Alleged violations of the Controlled Substances Act could result in billions of dollars in penalties.
Initial insights from Healthesystems’ annual industry survey.
Vaccine candidates from Pfizer-BioNTech and Moderna received EUAs, as did the first at-home test that delivers results in 30 minutes, and two treatments for the virus.
Navigating the workers’ comp process can be daunting for patients, and empathy can go a long way in improving outcomes.
A new report explores how COVID-19 has impacted telemedicine, as well as opportunities for expansion.
